Skip to product information
vial of Thymosin alpha-1 10mg with a gray cap, white label, and bold black text displaying dosage, batch number, and date, set against a neutral beige background
1/2
Thymosin alpha-1 10mg vial

Thymosin alpha-1 10mg vial

€65,00 EUR
Taxes included.

                                     NOT FOR HUMAN CONSUMPTION

Thymosin α1 is a 28–amino-acid synthetic peptide originally isolated from thymic extracts (thymosin fraction 5). It acts as a host-directed immunomodulator, enhancing antigen presentation (DC maturation), T-cell priming (Th1 bias), NK-cell cytotoxicity, and re-balancing dysregulated cytokine networks. Mechanistically it interfaces with pattern-recognition pathways (e.g., TLR2/7/9 on dendritic cells) and intracellular NF-κB/IRF signalling, improving antiviral and antitumour responses while limiting hyper-inflammation. Thymosin α1 is approved in several countries (ex-US/EU)—historically for chronic hepatitis B/C and adjunctive immunotherapy—not FDA-approved in the United States.

Additional Benefits of Thymosin α1 Now Under Investigation

Benefit Key take-aways
1 Antiviral host defence (HBV/HCV and beyond) In chronic hepatitis, Tα1 improves HBeAg seroconversion and ALT normalization and augments interferon/NA responses; newer work explores HDV and difficult-to-cure HBV phenotypes. <br/><em>Hepatology; Journal of Hepatology</em>
2 Vaccine adjuvancy Peri-vaccination courses increase seroconversion rates and antibody titres in hypo-responders (elderly, CKD, cirrhosis) and enhance T-cell responses to viral and tumour antigens. <br/><em>Vaccine; Human Vaccines & Immunotherapeutics</em>
3 Oncology (immunotherapy adjunct) Tα1 boosts DC cross-presentation and CD8⁺ priming, showing synergy with checkpoint inhibitors and chemo-immunotherapy in early trials for melanoma, HCC, and lung cancer. <br/><em>Cancer Immunology Research; Annals of Oncology</em>
4 Sepsis/critical-illness immunoparesis In lymphopenic/septic phenotypes, Tα1 restores HLA-DR on monocytes, increases IFN-γ/IL-2while reducing IL-6/TNF-α, with signals for lower secondary infection and mortality in select cohorts. <br/><em>Critical Care; Intensive Care Medicine</em>
5 Respiratory infections & ARDS (mixed evidence) Observational and small RCTs suggest reduced progression in viral pneumonias when given to lymphopenic patients; other trials are neutral, underscoring the need for phenotype-guided use. <br/><em>Chest; The Lancet Respiratory Medicine</em>
6 Immunosenescence & frailty Short courses increase naïve/memory T-cell markers, TRECs, and NK cytotoxicity in older adults, with fewer seasonal infections and better vaccine responses. <br/><em>Gerontology; Mechanisms of Ageing and Development</em>
7 Autoimmune “rebalance” (pilot) By promoting Treg stability and dampening pathologic Th17/Th2 signals, Tα1 is being explored as an adjunct in autoimmune thyroid disease, IBD, and psoriasis (early-phase data). <br/><em>Clinical Immunology; Journal of Autoimmunity</em>
8 Onco-hematology support Adjunct Tα1 shortens neutropenia duration, improves infection control, and may speed count recovery with chemotherapy or transplant conditioning. <br/><em>Bone Marrow Transplantation; Supportive Care in Cancer</em>
9 Metabolic-liver disease (NAFLD/NASH) Proof-of-concept studies show ALT/AST and CAP/MRI-PDFF improvements with immune/metabolic re-tuning; larger controlled trials are pending. <br/><em>Hepatology Communications; Liver International</em>

2. Molecular Mechanism of Action

2.1 Pharmacodynamics

Tα1 engages TLR2/7/9 (context-dependent) on dendritic cells and monocytes, promoting maturation (↑CD80/86, ↑HLA-DR) and IL-12 production; this licenses Th1 and CTL responses. In T cells, Tα1 enhances IL-2R (CD25)expression, IFN-γ production and survival signalling, while tempering excessive NF-κB activity in hyper-inflammatory states.

2.2 Down-stream Biology

Pathway Functional outcome Context
TLR→MyD88→NF-κB/IRFs DC maturation, type-1 cytokines, antiviral genes Innate/APC compartments
IL-12/IFN-γ axis Th1 polarization, CTL activation Adaptive T/NK cells
Treg/Th17 balance ↑ Treg stability, ↓ pathogenic Th17 Autoimmunity/inflammation
Antigen presentation ↑ HLA-DR, cross-presentation DCs/monocytes
NK effector pathways ↑ Perforin/Granzyme, cytotoxicity NK cells

3. Pharmacokinetics

  • Route: Subcutaneous is standard; IV used in some trials.

  • Absorption & t½: Rapid absorption; terminal half-life ~1.5–2.0 h (SC); pharmacodynamic effects outlast exposure via transcriptional re-programming.

  • Dosing paradigms (by indication/trials): 1.6 mg SC 2×/week (chronic hepatitis) for months; daily SC in short ICU/oncology courses; peri-vaccination short cycles.

  • Clearance: Peptidase degradation; no CYP interactions expected.

4. Pre-clinical and Translational Evidence

4.1 Chronic Viral Hepatitis

Multiple RCTs (legacy and modern) show improved biochemical and serologic responses with Tα1 alone or combined with interferon or nucleos(t)ide analogues; durability varies by genotype and baseline immunity.

4.2 Oncology

Tα1 enhances tumour antigen presentation and CD8⁺ infiltration; early clinical programmes suggest additive efficacywith PD-1/PD-L1 inhibitors and TACE in HCC, with acceptable tolerability.

4.3 Sepsis/Critical Care

Signals for reversal of immunoparesis (↑ mHLA-DR, ↑ lymphocyte counts) and lower secondary infections in phenotyped (lymphopenic) patients; heterogeneous results emphasize patient selection.

4.4 Vaccinology & Ageing

Consistent adjuvant effects in hypo-responders (older adults, CKD, cirrhosis), including higher seroprotection ratesand more durable cellular immunity.

Evidence quality note: Contemporary, well-controlled multicentre trials exist in hepatology and oncology; critical-care and NAFLD data are emerging and heterogeneous.

5. Emerging Clinical Interests

Field Rationale Current status
Checkpoint-inhibitor adjunct Bolster priming, reduce immune exhaustion Phase 2 signals; larger RCTs ongoing
Phenotype-guided sepsis care Treat lymphopenic immunoparesis Precision-trial designs in progress
NAFLD/NASH Immune-metabolic re-tuning of liver Pilot RCTs planned
Transplant infectious risk Improve antiviral defence without rejection Early feasibility
Elderly vaccine response Raise seroconversion/durability Positive small trials; policy studies needed

6. Safety and Tolerability

  • Common: Mild injection-site erythema, transient fatigue, headache, nausea.

  • Immune effects: Generally immunorestorative, not broadly immunosuppressive; monitor in autoimmuneconditions (rare flares).

  • Hepatic: Typically improves rather than worsens transaminases in hepatitis cohorts.

  • Drug interactions: Additive with interferons and antivirals; no known CYP issues.

  • Special populations: Use caution in transplant (balance infection risk vs rejection), pregnancy, and pediatricsettings outside trials.

Comparative safety matrix

Concern Thymosin α1 (synthetic) Thymalin (bovine extract) Interferon-α (for HBV/HCV, historical)
Composition Single 28-aa peptide Multi-peptide mixture Cytokine biologic
Immunologic action Host-directed restoration Broad immunocorrection Potent antiviral/immunostimulant
AE profile Mild, injection-site/fatigue Variable; extract-related Flu-like syndrome, depression, cytopenias
Regulatory footprint Approved ex-US/EU Regional (RU/CIS) Global (historical hepatitis use)

7. Regulatory Landscape

  • Approved (ex-US/EU): Adjunct treatment for chronic HBV/HCV, immune restoration, and vaccine adjuvancyin multiple countries (e.g., parts of Asia, ME/LatAm).

  • United States/EU: Not FDA/EMA-approved; accessible only via clinical trials or special pathways.

  • Quality: Use GMP-certified thymalfasin; avoid unregulated “research peptide” sources.

8. Future Directions

  • Phenotype-driven trials in lymphopenic sepsis, checkpoint-inhibitor combinations, and NAFLD/NASH with immune and imaging endpoints.

  • Biomarker-guided therapy (e.g., mHLA-DR, lymphocyte counts, cytokine signatures) to select responders and time courses.

  • Combination immunotherapy frameworks (with PD-1/PD-L1, oncolytic viruses, TLR agonists) to deepen antitumour immunity.

  • Public-health integration as adjuvant for hard-to-immunize groups (elderly, CKD, cirrhosis, immunosuppressed).

  • Mechanistic mapping of TLR bias and downstream IRF vs NF-κB balance to predict efficacy and safety.

Selected References

  • Hepatology; Journal of Hepatology — Thymosin α1 in chronic viral hepatitis (monotherapy and combination).

  • Vaccine; Human Vaccines & Immunotherapeutics — Adjuvant effects on seroconversion and T-cell responses.

  • Cancer Immunology Research; Annals of Oncology — Combinatorial immunotherapy data (checkpoint inhibitors, HCC regimens).

  • Critical Care; Intensive Care Medicine — Reversal of immunoparesis in sepsis and critical illness.

  • Gerontology; Mechanisms of Ageing and Development — Immunosenescence trials and infection outcomes.

  • Bone Marrow Transplantation; Supportive Care in Cancer — Onco-hematology supportive-care studies.

  • Hepatology Communications; Liver International — Early NAFLD/NASH investigations and biomarkers.